Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Brentuximab Vedotin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    		 Select Age Range:
    Select Trial Status:
    		 Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    22 result(s) found for: Brentuximab Vedotin. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-004128-39 Sponsor Protocol Number: C25006 Start Date*: 2013-07-08
    Sponsor Name:Millennium Pharmaceuticals, Inc
    Full Title: A Phase 4, Open–label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
    Medical condition: Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10002235 Anaplastic large cell lymphomas T- and-cell types HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) PT (Completed) ES (Completed) PL (Completed) HU (Completed) HR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002012-46 Sponsor Protocol Number: BV-ABVD Start Date*: 2012-11-15
    Sponsor Name:AZIENDA OSPEDALIERA POLICLINICO DI MODENA
    Full Title: A pilot phase II study to assess the efficacy of Brentuximab Vedotin administered sequentally with ABVD chemotherapy in patients with untreated Hodgkin Lymphoma
    Medical condition: Previously untreated patients with classical Hodgkin Lymphoma according to the World Health Organisation (WHO) classification
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020205 Hodgins LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-003286-28 Sponsor Protocol Number: CA209-436 Start Date*: 2016-04-25
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression
    Medical condition: Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004851 10029606 Non-Hodgkin's lymphomas transformed recurrent HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) FR (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-002347-41 Sponsor Protocol Number: CA209-744 Start Date*: Information not available in EudraCT
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Risk-based, response-adapted, Phase II open-label trial of nivolumab + brentuximab vedotin (N + Bv) for children, adolescents, and young adults with relapsed/refractory (R/R) CD30 + classic Hodgkin...
    Medical condition: Relapsed/refractory (R/R) CD30 + classic Hodgkin lymphoma (cHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Completed) ES (Ongoing) IE (Completed) DE (Completed) GB (GB - no longer in EU/EEA) NL (Completed) PL (Completed) Outside EU/EEA IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001211-21 Sponsor Protocol Number: HO136 Start Date*: 2017-04-14
    Sponsor Name:HOVON Foundation
    Full Title: Phase I-II study combining Brentuximab Vedotin with second line salvage chemotherapy (R-DHAP) in CD30 positive diffuse large B-cell lymphoma patients refractory to first line chemotherapy or in fir...
    Medical condition: CD30 positive diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003689-28 Sponsor Protocol Number: BrEPEM-LH-22017 Start Date*: 2018-04-05
    Sponsor Name:GELTAMO (Grupo Español de Linfomas y trasplante autólogo de médula osea)
    Full Title: A Phase Ib/II Trial of Combined SGN-35 (BrentuximabVedotin) Therapy with cyclophosphamide, procarbazine, prednisone, etoposide and mitoxantrone (BrEPEM) for Older Patients with Untreated Hodgkin Ly...
    Medical condition: Older Patients with Untreated Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080208 Classical Hodgkin lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-001263-70 Sponsor Protocol Number: IIBSP-CAR-2019-30 Start Date*: 2020-03-03
    Sponsor Name:Institut de Recerca H. de la Santa Creu i Sant Pau
    Full Title: Immunotherapy with differential, adult, autologous, peripheral blood cells, expanded and transduced (genetically modified) using a lentiviral vector to express a chimeric receptor with anti-CD30 sp...
    Medical condition: Classic Hodgkin lymphoma and T-cell lymphoma with CD30 expression
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002544-32 Sponsor Protocol Number: UCL/15/0515 Start Date*: 2018-03-01
    Sponsor Name:University College London
    Full Title: A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first ...
    Medical condition: Relapsed/refractory Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020266 Hodgkin's disease recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020267 Hodgkin's disease refractory PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2019-002746-21 Sponsor Protocol Number: GELTAMO18-HL Start Date*: 2020-04-29
    Sponsor Name:Fundación GELTAMO
    Full Title: A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Refractory Classical Hodgkin’s Lymphoma, Followed by Brentux...
    Medical condition: Patients with Relapsed /Refractory Classical Hodgkin's Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080208 Classical Hodgkin lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) GR (Trial now transitioned) HR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020363-21 Sponsor Protocol Number: SGN35-010 Start Date*: 2010-11-09
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: An open-label, phase 2/3, treatment-option protocol of brentuximab vedotin in patients with progression of Hodgkin lymphoma
    Medical condition: Patients who were on the placebo arm and experienced progression of HL while participating in the SGN35-005 clinical study
    Disease: Version SOC Term Classification Code Term Level
    12.1 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) ES (Completed) IT (Completed) BG (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000182-37 Sponsor Protocol Number: BREACH Start Date*: 2014-08-29
    Sponsor Name:LYSARC
    Full Title: BRENTUXIMAB VEDOTIN ASSOCIATED WITH CHEMOTHERAPY IN UNTREATED PATIENTS WITH STAGE I/II UNFAVOURABLE HODGKIN LYMPHOMA - A RANDOMIZED PHASE II LYSA-FIL-EORTC INTERGROUP STUDY
    Medical condition: Untreated patients with histologically confirmed CD30+ classical Hodgkin lymphoma (stage I/II), aged > or = 18 and < or = 60 years old, with at least one unfavourable clinical pronostic factor
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020328 Hodgkin's lymphoma LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) IT (Ongoing) DK (Completed) NL (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2015-005053-12 Sponsor Protocol Number: MK3475-204 Start Date*: 2016-06-01
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractory Classical Hodgkin Lymphoma
    Medical condition: Relapsed or refractory classical Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10020328 Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-004482-24 Sponsor Protocol Number: MK3475-087 Start Date*: 2015-06-02
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase II clinical trial of MK-3475 (pembrolizumab) in subjects with relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL)
    Medical condition: Hodgkin lymphoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NO (Completed) ES (Completed) NL (Prematurely Ended) DE (Completed) AT (Completed) HU (Completed) IE (Completed) FR (Completed) GB (GB - no longer in EU/EEA) GR (Completed)
    Trial results: View results
    EudraCT Number: 2020-002686-33 Sponsor Protocol Number: SGN35-031 Start Date*: 2020-12-23
    Sponsor Name:Seattle Genetics, Inc.
    Full Title: A Randomized, Double-blind, Placebo-Controlled, Active Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relap...
    Medical condition: diffuse large B-cell lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Prematurely Ended) DK (Trial now transitioned) DE (Completed) CZ (Trial now transitioned) PL (Trial now transitioned) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-001509-42 Sponsor Protocol Number: CA209-205 Start Date*: 2014-07-11
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: Non-Comparative, Multi-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab (BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects
    Medical condition: Hodgkin Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) BE (Completed) DE (Completed) IT (Completed) NL (Completed) ES (Ongoing) CZ (Completed) GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2011-005450-60 Sponsor Protocol Number: C25003 Start Date*: 2013-02-09
    Sponsor Name:Millennium Pharmaceuticals, Inc
    Full Title: A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma
    Medical condition: Advanced Classical Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) HU (Trial now transitioned) GB (GB - no longer in EU/EEA) BE (Trial now transitioned) IT (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000498-35 Sponsor Protocol Number: 1537 Start Date*: 2019-03-12
    Sponsor Name:European Organisation for Research and Treatment of Cancer (EORTC)
    Full Title: Very early FDG-PET-response adapted targeted therapy for advanced Hodgkin lymphoma: a single-arm phase II study
    Medical condition: Advanced stage Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10080208 Classical Hodgkin lymphoma LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020206 Hodgkin's disease PT
    20.0 10005329 - Blood and lymphatic system disorders 10020243 Hodgkin's disease NEC HLT
    20.0 10005329 - Blood and lymphatic system disorders 10025319 Lymphomas Hodgkin's disease HLGT
    20.0 10005329 - Blood and lymphatic system disorders 10005329 Blood and lymphatic system disorders SOC
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) SK (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004954-31 Sponsor Protocol Number: DS3201-A-U202 Start Date*: 2021-07-29
    Sponsor Name:DAIICHI SANKYO, INC.
    Full Title: Single-Arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma
    Medical condition: Relapsed/Refractory Peripheral T-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025310 Lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) NL (Completed) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-001123-13 Sponsor Protocol Number: VS-0145-225 Start Date*: 2019-12-02
    Sponsor Name:Secura Bio, Inc
    Full Title: A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
    Medical condition: Peripheral T-cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042971 T-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-002556-32 Sponsor Protocol Number: ADCT-301-201 Start Date*: 2019-12-16
    Sponsor Name:ADC Therapeutics SA
    Full Title: A Phase 2, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients with Relapsed or Refractory Hodgkin Lymphoma
    Medical condition: Relapsed or Refractory Hodgkin Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10080208 Classical Hodgkin lymphoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020328 Hodgkin's lymphoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020267 Hodgkin's disease refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020234 Hodgkin's disease mixed cellularity refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10020233 Hodgkin's disease mixed cellularity recurrent PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) PL (Completed) FR (Completed) CZ (Completed) HU (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 11 23:02:15 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA